Latest news
15 September 2021
Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces extension of its fundraising round to a current aggregate total of US $125 million (£92 million GBP). The round was led by Bridford Investments Limited and Novator Partners. Demand for Touchlight’s proprietary synthetic DNA vector, dbDNA™, has grown rapidly … Continued
28 July 2021
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
Touchlight’s doggybone DNA™ to be used in Pandemic Prevention Platform (P3) programme funded by Defense Advanced Research Projects Agency (DARPA) • For the first time, novel synthetic DNA combined with state-of-the-art delivery will be used to deliver neutralising antibody therapies and enable faster pandemic response • Touchlight recently raised £42 million ($58 million) to expand … Continued
11 March 2021
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand Completed facility will have capacity to manufacture up to 1 kg GMP DNA per month, enough for more than 1 billion Covid-19 vaccine doses Company’s growth driven by exceptional demand in all areas of genetic medicine, including mRNA and viral vectors for Covid-19 … Continued
3 December 2020
Touchlight appoints Satish Muchakayala as Director of Regulatory Affairs
Touchlight announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. Hampton, UK – 03 December 2020 Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. In … Continued
27 April 2020
Touchlight appoints Dr. Helen Horton as Chief Research Officer
Former J&J Senior Scientific Director and immunology expert joins at a pivotal time Touchlight driving its dbDNA technology towards clinical development in therapeutic and prophylactic vaccines Hampton, UK – 27 April 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Dr. Helen Horton as … Continued
17 January 2019
Touchlight welcomes Anjum Ahmad as Chief Financial Officer
Anjum Ahmad brings extensive insight in the UK’s life sciences sector having been the longstanding Group Finance Director of Touchstone Innovations Plc (formerly Imperial Innovations) – the AIM listed venture capital investor in early stage science. In his former role at Touchstone he was one of the four-person senior executive team, presenting over £200m of … Continued
18 November 2018
Touchlight appoints Dr. Michael Linden as Chief Scientific Officer
Touchlight Genetics Ltd, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announced the appointment of Dr. Michael Linden as Chief Scientific Officer (CSO). In his role Dr. Linden will be responsible for leading the Company’s discovery pipeline and translational research efforts in genetic medicine, deploying their doggybone DNA technology … Continued
2 November 2018
Touchlight awarded runner-up in Spectator Economic Disruptor Award
Earlier this year, The Spectator and Julius Baer launched the inaugural Economic Disruptor Awards to celebrate the most creative entrepreneurs in the UK. Over the past six months, over 100 nominations have been reviewed. On the 1st of November, the winners were announced at a gala dinner hosted by Andrew Neil, Chairman of The Spectator, and attended by … Continued
24 October 2018
Touchlight announces collaboration with Janssen Biotech
Hampton, London, United Kingdom, 23rd October 2018 Touchlight Genetics Ltd., a biotechnology company developing a novel, synthetic DNA vector platform known as “doggybone” DNA, announced a collaboration with Janssen Biotech, Inc. to evaluate the application of doggybone DNA in the development of multiple genetic therapies, in the fields of infectious disease and oncology. The agreement … Continued
27 March 2018
Touchlight opens GMP production facility
Touchlight Genetics Ltd has established a GMP facility to support development of therapeutic products that incorporate the company’s revolutionary dbDNA™ vector technology. The facility will support clinical and commercial production for both in-house and partnered programs. Touchlight has developed a revolutionary DNA vector known as doggybone™ DNA (dbDNA) which enables uniquely differentiated products across multiple … Continued
6 December 2017
Touchlight cited in life sciences sector deal
Today, the UK government has announced that they have agreed with the life sciences sector a transformative new Sector Deal as a part of the Industrial Strategy. The Life Sciences Sector Deal will help ensure new pioneering treatments and medical technologies are produced in the UK, improving patient lives and driving economic growth. The deal … Continued
6 December 2017
Touchlight receives grand funding for DNA templated nanowire inks project
Touchlight and Newcastle University – DNA templated compound semiconductor nanowires for low-cost pollution sensors and quantum dots Touchlight and Newcastle University have been awarded grant funding from the UK’s innovation agency, Innovate UK, to advance a commercial manufacturing process to produce ultra-thin compound semiconductor nanowires using a DNA template. The process produces nanowire ‘inks’ that … Continued